CSIMarket Company Name, Ticker, Competitors, else..
 
Agenus Inc  (NASDAQ: AGEN)
 
Price: $7.6100 $-0.05 -0.653%
Day's High: $7.760000228881836 Week Perf: -8.97 %
Day's Low: $ 7.50 30 Day Perf: 1.47 %
Volume (M): 719,261 52 Wk High: $ 8.85
Volume (M$): $ 0 52 Wk Avg: $4.16
Open: $7.68 52 Wk Low: $2.71



 Market Capitalization (Millions $) 315
 Shares Outstanding (Millions) 41
 Employees 81
 Revenues (TTM) (Millions $) 133
 Net Income (TTM) (Millions $) 92
 Cash Flow (TTM) (Millions $) 24
 Capital Exp. (TTM) (Millions $) 0

Business Description


Agenus Inc. is a biotechnology company based in Lexington, Massachusetts. The company is focused on the discovery, development, and commercialization of immune-based therapies for the treatment of cancer and other diseases. Agenus utilizes its proprietary technologies to develop novel antibodies, vaccines, and adjuvants to activate the immune system against cancer cells. The company's product pipeline includes both clinical and pre-clinical stage candidates targeting various types of cancer. Agenus also collaborates with other pharmaceutical companies to advance its immunotherapy programs.


   Company Address: 3 Forbes Road Lexington 2421 MA
   Company Phone Number: 674-4400   Stock Exchange / Ticker: NASDAQ AGEN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
MRNA        1.04% 
REPL        4.01% 
PSTV   -0.83%    
• View Complete Report
   



Business Update

Agenus Pushes Frontiers Compassionate Access, Global Trials, and AI Innovations Lead Q3 Advancements,

Published Mon, Nov 10 2025 3:01 PM UTC

Agenus Inc. Reports Q3 2025 Achievements: Regulatory Progress, New Data Revelations, and AI-Driven Collaborations LEXINGTON, Mass. Agenus Inc. (Nasdaq: AGEN) has announced its financial results for the third quarter of 2025, showcasing significant clinical and regulatory advancements. These developments reflect the company s commitment to innovative solutions in the field of...
Business Update

Advancing Oncology Breakthrough Survival Outcomes with Botensilimab and Balstilimab Combination in Refract...

Published Mon, Oct 20 2025 9:24 AM UTC

In the rapidly evolving field of immuno-oncology, Agenus Inc. (Nasdaq: AGEN) has marked a significant milestone with the presentation of new data demonstrating promising survival outcomes for patients with advanced-stage cancer undergoing treatment with a combination of botensilimab (BOT) and balstilimab (BAL). This novel therapeutic combination has emerged as a potential b...
Business Update

A New Dawn in Cancer Treatment France Grants Compassionate Access to Agenus Innovative BOT/BAL Therapy,

Published Wed, Sep 10 2025 4:35 AM UTC

Accessing Hope: France Provides Compassionate Use for Agenus BOT/BAL Therapy in Colorectal CancerIn a groundbreaking development for cancer treatment, Agenus Inc. has announced that its innovative BOT/BAL combination therapy featuring botensilimab and balstilimab is now available to eligible patients in France suffering from refractory metastatic colorectal cancer (MCC) th...
Business Update

“Immuno-Oncology Breakthroughs Agenus Pioneers Hope for Liver Cancer Patients with Promising Drug Combinat...

Published Sat, Apr 26 2025 7:58 AM UTC

In a notable stride toward innovating cancer care, Agenus Inc. (Nasdaq: AGEN), a leading company in the immuno-oncology landscape, has showcased compelling data from its ongoing Phase 1 study focusing on botensilimab (BOT) and balstilimab (BAL) in treating pretreated hepatocellular carcinoma (HCC). These findings were presented at the prestigious American Association for Can...
Business Update

Advancements in Immuno-Oncology Updated Phase 1 Data for Botensilimab and Balstilimab in Hepatocellular Carcinoma

Published Fri, Apr 25 2025 7:12 PM UTC

: The landscape of hepatocellular carcinoma (HCC) treatment continues to evolve with the ongoing developments in immuno-oncology. Agenus Inc. has made significant strides with its dual therapy of botensilimab (BOT) and balstilimab (BAL), which demonstrates promise in pretreated, difficult-to-treat liver cancer patients. This article reviews the latest findings from the Pha...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 3.06
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.37
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.08
Working Capital Ratio 0.19
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 2.49 $
Revenues (TTM) 3.21 $
Cash Flow (TTM) 0.57 $
Cash 0.45 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,638,185
Net Income per Employee (TTM) 1,135,037
Receivable Turnover Ratio (TTM) 22.44
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.65

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 32.72 %
Net Margin (MRQ) -1.64 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 44.76 %
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Agenus Inc's Segments
Pre Commercial Product Revenue    31.76 % of total Revenue
Non Cash Royalty Revenue Related to the Sale of Future Royalties    165.97 % of total Revenue
US    197.73 % of total Revenue
Non Cash Royalty Revenue    165.97 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.